The options were granted in accordance with Nasdaq Listing Rule 5635(4).
The options have an exercise price of
About
Contact:
Email: mcarrasco@akebia.com
(C) 2024 Electronic News Publishing, source
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.32 USD | -1.49% | -3.65% | +6.45% |
Apr. 23 | Averoa Seeks EU Approval for Chronic Kidney Disease Drug | MT |
Apr. 16 | Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited Enters into Second Amendment to the Supply Agreement | CI |
The options were granted in accordance with Nasdaq Listing Rule 5635(4).
The options have an exercise price of
About
Contact:
Email: mcarrasco@akebia.com
(C) 2024 Electronic News Publishing, source
1st Jan change | Capi. | |
---|---|---|
+6.45% | 281M | |
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B |